Antibody – VX70 Oncology

VX70 is a novel, high affinity VEGF-specific human IgG1 antibody designed to have broad efficacy as a cancer therapeutic. In studies comparing activity to a leading commercial antibody currently used in cancer therapy, VX70 compared favorably in its ability to block binding to cognate VEGF receptors (type I and II) and in reducing tumor burden in a mouse xenograft model of rhabdomyosarcoma.

Vaccinex has completed proof of concept testing of our lead antibody and is interested in partnering this product for development or co-development.

Figure 1. The VX70 antibody effectively reduces the growth of A-673 tumor cells in vivo. Tumor bearing mice were divided intro three groups of 12 mice each and treated twice weekly with 100ug of antibody ending at day 22. Treatment groups included VX70, a commercial anti-VEGF therapeutic antibody, and an irrelevant human IgG control. The data demonstrate that treatment with VX70 inhibited tumor growth comparably to the commercial antibody. Treatment with VX70 resulted in an 87% tumor growth delay relative to IgG (logrank results were significant (P<0.0005). Note too that VX70 and the commercial antibody were not statistically different in terms of tumor growth delay.

Figure 2. VX70 effectively blocks target from binding to native receptors. Increasing concentrations of antibody were pre-incubated with soluble ligand and then added to an ELISA plate coated with either receptor type I or II as indicated. Increasing amounts of VX70 result in decreased binding of antigen to either receptor.